EUVIMEDEUVIMED entdecken
Fallbericht

IDH ‐negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site—A diagnostic pitfall

Tetsuya Sekita iD, Akihiko Yoshida iD, Akira Kawai, Hitoshi Ichikawa iD, Eisuke Kobayashi

Genes, Chromosomes and Cancer · 2023

DOI: 10.1002/gcc.23204 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2023. Verfasst von Tetsuya Sekita und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dedifferentiated chondrosarcoma is a subtype of chondrosarcoma with a biphasic histological appearance of a chondrosarcoma component transitioning to a high‐grade, noncartilaginous sarcoma. It is particularly difficult to confirm the diagnosis when a sarcoma lacking cartilaginous component occurs at a distant location from the primary lesion. The patient was a 72‐year‐old woman with multiple lesions in the pelvis, lungs, and liver, 18 months after resection of grade 2 central chondrosarcoma of the sternum. Imaging showed no cartilage component in any location. Although a needle biopsy from the pelvic region confirmed the diagnosis as high‐grade sarcoma without a cartilage component, it was difficult to distinguish between a new primary sarcoma and metachronous metastatic lesions from patient's known prior dedifferentiated chondrosarcoma. We therefore performed a comparative molecular analysis by whole‐exome sequencing of the biopsy sample and the resected sternal central chondrosarcoma. Both lesions had no IDH1/2 mutations but shared 19 somatic mutations and wide‐range chromosomal losses, indicating similar origin. This case illustrates the challenge is coupling a diagnosis of metastatic dedifferentiated chondrosarcoma when no chondroid component is evident. Our study also highlights the benefit of genomic analysis in this differential diagnosis, especially in the context of dedifferentiated chondrosarcoma lacking IDH 1/2 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaBone NeoplasmsFemaleHumansAgedMutationChromosome Aberrations

Stichwörter der Autor:innen

chondrosarcomadedifferentiationmetachronous

Autor:innen und Institutionen

  • Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Tetsuya Sekita, Akihiko Yoshida, Hitoshi Ichikawa

Zitieren

APA

Sekita, T., Yoshida, A., Kawai, A., Ichikawa, H., & Kobayashi, E. (2023). IDH ‐negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site—A diagnostic pitfall. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23204

Vancouver

Sekita T, Yoshida A, Kawai A, Ichikawa H, Kobayashi E. IDH ‐negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site—A diagnostic pitfall. Genes, Chromosomes and Cancer. 2023. doi:10.1002/gcc.23204

BibTeX
@article{Sekita2023,
  author = {Sekita, Tetsuya and Yoshida, Akihiko and Kawai, Akira and Ichikawa, Hitoshi and Kobayashi, Eisuke},
  title = {IDH ‐negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site—A diagnostic pitfall},
  journal = {Genes, Chromosomes and Cancer},
  year = {2023},
  doi = {10.1002/gcc.23204}
}
Kostenlos starten →